Physician profile
Brandon Kitay
NPI 1235549353
$58,568.88
in general payments reported to CMS, 2019-2025
8 companies · $5,484 in 2025
The $5,484 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,087 · 2020: $2,970 · 2021: $2,060 · 2022: $16K · 2023: $12K · 2024: $17K · 2025: $5,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $5,558 · Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,573.50 |
| Travel and Lodging | $5,558.33 |
| Food and Beverage | $994.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,256.58 | 2022-2025 | |
| Biogen, INC. | $12,064.06 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,060.35 | 2020-2025 | Rejoyn |
| Boehringer Ingelheim International Gmbh | $4,833.51 | 2024-2025 | |
| Sage Therapeutics, LLC | $3,120.00 | 2024 | |
| Janssen Pharmaceuticals, INC | $3,087.26 | 2019 | |
| Merck Sharp & Dohme LLC | $3,022.50 | 2022 | |
| Janssen Scientific Affairs, LLC | $124.62 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Kitay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.